Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study

A. Cortellini; K. Cannita; M. Tiseo; D.L. Cortinovis; J.G.J.V. Aerts; C. Baldessari; R. Giusti; M.G. Ferrara; E. D'Argento; F. Grossi; A. Guida; R. Berardi; A. Morabito; C. Genova; L. Antonuzzo; F. Mazzoni; A. De Toma; D. Signorelli; A. Gelibter; G. Targato; F. Rastelli; R. Chiari; D. Rocco; S. Gori; M. De Tursi; G. Mansueto; F. Zoratto; M. Filetti; S. Bracarda; F. Citarella; R. Marco; L. Cantini; O. Nigro; S. Buti; G. Minuti; L. Landi; S. Ricciardi; M.R. Migliorino; S. Natalizio; C. Simona; M. De Filippis; G. Metro; V. Adamo; A. Russo; G.P. Spinelli; M. Di Maio; G.L. Banna; A. Friedlaender; A. Addeo; D.J. Pinato; C. Ficorella; G. Porzio

doi:10.1016/j.ejca.2021.02.005

Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study

A. Cortellini, K. Cannita, M. Tiseo, D.L. Cortinovis, J.G.J.V. Aerts, C. Baldessari, R. Giusti, M.G. Ferrara, E. D'Argento, F. Grossi, A. Guida, R. Berardi, A. Morabito, C. Genova, L. Antonuzzo, F. Mazzoni, A. De Toma, D. Signorelli, A. Gelibter, G. TargatoF. Rastelli, R. Chiari, D. Rocco, S. Gori, M. De Tursi, G. Mansueto, F. Zoratto, M. Filetti, S. Bracarda, F. Citarella, R. Marco, L. Cantini, O. Nigro, S. Buti, G. Minuti, L. Landi, S. Ricciardi, M.R. Migliorino, S. Natalizio, C. Simona, M. De Filippis, G. Metro, V. Adamo, A. Russo, G.P. Spinelli, M. Di Maio, G.L. Banna, A. Friedlaender, A. Addeo, D.J. Pinato, C. Ficorella, G. Porzio

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	24-35
Number of pages	12
Journal	European Journal of Cancer
Volume	148
DOIs	https://doi.org/10.1016/j.ejca.2021.02.005
Publication status	Published - 2021

Keywords

Immunotherapy
Non-small cell lung cancer
PD-L1
Pembrolizumab
Performance status
Post-progression
Radiation therapy
Radiotherapy
corticosteroid
pembrolizumab
programmed death 1 ligand 1
adult
aged
Article
bone metastasis
cancer chemotherapy
cancer mortality
cancer patient
cancer radiotherapy
central nervous system metastasis
clinical outcome
cohort analysis
comparative study
descriptive research
doublet chemotherapy
drug substitution
drug withdrawal
ECOG Performance Status
female
follow up
human
liver metastasis
lung carcinogenesis
major clinical study
male
multicenter study
non small cell lung cancer
overall survival
priority journal
protein expression
sex difference
single drug dose

Access to Document

10.1016/j.ejca.2021.02.005

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85102300170&doi=10.1016%2fj.ejca.2021.02.005&partnerID=40&md5=a7103ea2bb04278c69b63e9922c77064

Cite this

Cortellini, A., Cannita, K., Tiseo, M., Cortinovis, D. L., Aerts, J. G. J. V., Baldessari, C., Giusti, R., Ferrara, M. G., D'Argento, E., Grossi, F., Guida, A., Berardi, R., Morabito, A., Genova, C., Antonuzzo, L., Mazzoni, F., De Toma, A., Signorelli, D., Gelibter, A., ... Porzio, G. (2021). Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study. European Journal of Cancer, 148, 24-35. https://doi.org/10.1016/j.ejca.2021.02.005

Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study. / Cortellini, A.; Cannita, K.; Tiseo, M.; Cortinovis, D.L.; Aerts, J.G.J.V.; Baldessari, C.; Giusti, R.; Ferrara, M.G.; D'Argento, E.; Grossi, F.; Guida, A.; Berardi, R.; Morabito, A.; Genova, C.; Antonuzzo, L.; Mazzoni, F.; De Toma, A.; Signorelli, D.; Gelibter, A.; Targato, G.; Rastelli, F.; Chiari, R.; Rocco, D.; Gori, S.; De Tursi, M.; Mansueto, G.; Zoratto, F.; Filetti, M.; Bracarda, S.; Citarella, F.; Marco, R.; Cantini, L.; Nigro, O.; Buti, S.; Minuti, G.; Landi, L.; Ricciardi, S.; Migliorino, M.R.; Natalizio, S.; Simona, C.; De Filippis, M.; Metro, G.; Adamo, V.; Russo, A.; Spinelli, G.P.; Di Maio, M.; Banna, G.L.; Friedlaender, A.; Addeo, A.; Pinato, D.J.; Ficorella, C.; Porzio, G.

In: European Journal of Cancer, Vol. 148, 2021, p. 24-35.

Research output: Contribution to journal › Article › peer-review

Cortellini, A, Cannita, K, Tiseo, M, Cortinovis, DL, Aerts, JGJV, Baldessari, C, Giusti, R, Ferrara, MG , D'Argento, E , Grossi, F , Guida, A, Berardi, R, Morabito, A, Genova, C, Antonuzzo, L, Mazzoni, F, De Toma, A, Signorelli, D, Gelibter, A, Targato, G, Rastelli, F, Chiari, R, Rocco, D, Gori, S, De Tursi, M, Mansueto, G , Zoratto, F, Filetti, M, Bracarda, S, Citarella, F, Marco, R, Cantini, L, Nigro, O, Buti, S, Minuti, G, Landi, L, Ricciardi, S, Migliorino, MR, Natalizio, S, Simona, C, De Filippis, M, Metro, G, Adamo, V, Russo, A, Spinelli, GP, Di Maio, M, Banna, GL, Friedlaender, A, Addeo, A, Pinato, DJ, Ficorella, C & Porzio, G 2021, 'Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study', European Journal of Cancer, vol. 148, pp. 24-35. https://doi.org/10.1016/j.ejca.2021.02.005

Cortellini, A. ; Cannita, K. ; Tiseo, M. ; Cortinovis, D.L. ; Aerts, J.G.J.V. ; Baldessari, C. ; Giusti, R. ; Ferrara, M.G. ; D'Argento, E. ; Grossi, F. ; Guida, A. ; Berardi, R. ; Morabito, A. ; Genova, C. ; Antonuzzo, L. ; Mazzoni, F. ; De Toma, A. ; Signorelli, D. ; Gelibter, A. ; Targato, G. ; Rastelli, F. ; Chiari, R. ; Rocco, D. ; Gori, S. ; De Tursi, M. ; Mansueto, G. ; Zoratto, F. ; Filetti, M. ; Bracarda, S. ; Citarella, F. ; Marco, R. ; Cantini, L. ; Nigro, O. ; Buti, S. ; Minuti, G. ; Landi, L. ; Ricciardi, S. ; Migliorino, M.R. ; Natalizio, S. ; Simona, C. ; De Filippis, M. ; Metro, G. ; Adamo, V. ; Russo, A. ; Spinelli, G.P. ; Di Maio, M. ; Banna, G.L. ; Friedlaender, A. ; Addeo, A. ; Pinato, D.J. ; Ficorella, C. ; Porzio, G. / Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study. In: European Journal of Cancer. 2021 ; Vol. 148. pp. 24-35.

@article{52fcd1f3c02741eb8bc78186f1b33e41,

title = "Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study",

keywords = "Immunotherapy, Non-small cell lung cancer, PD-L1, Pembrolizumab, Performance status, Post-progression, Radiation therapy, Radiotherapy, corticosteroid, pembrolizumab, programmed death 1 ligand 1, adult, aged, Article, bone metastasis, cancer chemotherapy, cancer mortality, cancer patient, cancer radiotherapy, central nervous system metastasis, clinical outcome, cohort analysis, comparative study, descriptive research, doublet chemotherapy, drug substitution, drug withdrawal, ECOG Performance Status, female, follow up, human, liver metastasis, lung carcinogenesis, major clinical study, male, multicenter study, non small cell lung cancer, overall survival, priority journal, protein expression, sex difference, single drug dose",

author = "A. Cortellini and K. Cannita and M. Tiseo and D.L. Cortinovis and J.G.J.V. Aerts and C. Baldessari and R. Giusti and M.G. Ferrara and E. D'Argento and F. Grossi and A. Guida and R. Berardi and A. Morabito and C. Genova and L. Antonuzzo and F. Mazzoni and {De Toma}, A. and D. Signorelli and A. Gelibter and G. Targato and F. Rastelli and R. Chiari and D. Rocco and S. Gori and {De Tursi}, M. and G. Mansueto and F. Zoratto and M. Filetti and S. Bracarda and F. Citarella and R. Marco and L. Cantini and O. Nigro and S. Buti and G. Minuti and L. Landi and S. Ricciardi and M.R. Migliorino and S. Natalizio and C. Simona and {De Filippis}, M. and G. Metro and V. Adamo and A. Russo and G.P. Spinelli and {Di Maio}, M. and G.L. Banna and A. Friedlaender and A. Addeo and D.J. Pinato and C. Ficorella and G. Porzio",

note = "Export Date: 10 June 2021 CODEN: EJCAE Correspondence Address: Cortellini, A.; Imperial College London, United Kingdom; email: a.cortellini@imperial.ac.uk",

year = "2021",

doi = "10.1016/j.ejca.2021.02.005",

language = "English",

volume = "148",

pages = "24--35",

journal = "European Journal of Cancer",

issn = "0959-8049",

}

TY - JOUR

T1 - Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study

AU - Cortellini, A.

AU - Cannita, K.

AU - Tiseo, M.

AU - Cortinovis, D.L.

AU - Aerts, J.G.J.V.

AU - Baldessari, C.

AU - Giusti, R.

AU - Ferrara, M.G.

AU - D'Argento, E.

AU - Grossi, F.

AU - Guida, A.

AU - Berardi, R.

AU - Morabito, A.

AU - Genova, C.

AU - Antonuzzo, L.

AU - Mazzoni, F.

AU - De Toma, A.

AU - Signorelli, D.

AU - Gelibter, A.

AU - Targato, G.

AU - Rastelli, F.

AU - Chiari, R.

AU - Rocco, D.

AU - Gori, S.

AU - De Tursi, M.

AU - Mansueto, G.

AU - Zoratto, F.

AU - Filetti, M.

AU - Bracarda, S.

AU - Citarella, F.

AU - Marco, R.

AU - Cantini, L.

AU - Nigro, O.

AU - Buti, S.

AU - Minuti, G.

AU - Landi, L.

AU - Ricciardi, S.

AU - Migliorino, M.R.

AU - Natalizio, S.

AU - Simona, C.

AU - De Filippis, M.

AU - Metro, G.

AU - Adamo, V.

AU - Russo, A.

AU - Spinelli, G.P.

AU - Di Maio, M.

AU - Banna, G.L.

AU - Friedlaender, A.

AU - Addeo, A.

AU - Pinato, D.J.

AU - Ficorella, C.

AU - Porzio, G.

N1 - Export Date: 10 June 2021 CODEN: EJCAE Correspondence Address: Cortellini, A.; Imperial College London, United Kingdom; email: a.cortellini@imperial.ac.uk

PY - 2021

Y1 - 2021

KW - Immunotherapy

KW - Non-small cell lung cancer

KW - PD-L1

KW - Pembrolizumab

KW - Performance status

KW - Post-progression

KW - Radiation therapy

KW - Radiotherapy

KW - corticosteroid

KW - pembrolizumab

KW - programmed death 1 ligand 1

KW - adult

KW - aged

KW - Article

KW - bone metastasis

KW - cancer chemotherapy

KW - cancer mortality

KW - cancer patient

KW - cancer radiotherapy

KW - central nervous system metastasis

KW - clinical outcome

KW - cohort analysis

KW - comparative study

KW - descriptive research

KW - doublet chemotherapy

KW - drug substitution

KW - drug withdrawal

KW - ECOG Performance Status

KW - female

KW - follow up

KW - human

KW - liver metastasis

KW - lung carcinogenesis

KW - major clinical study

KW - male

KW - multicenter study

KW - non small cell lung cancer

KW - overall survival

KW - priority journal

KW - protein expression

KW - sex difference

KW - single drug dose

U2 - 10.1016/j.ejca.2021.02.005

DO - 10.1016/j.ejca.2021.02.005

M3 - Article

VL - 148

SP - 24

EP - 35

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

ER -